- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
- MAA review of TA704 and TA862
- Process:
- STA Standard
- ID number:
- 5121
Provisional Schedule
- Committee meeting: 2:
- 10 March 2026
- Expected publication:
- 07 May 2026
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email TACommA@nice.org.uk
Stakeholders
- Companies sponsors
- Daiichi Sankyo UK Ltd
- Others
- Department of Health and Social Care
- NHS England
- Welsh Government
- Patient carer groups
- Breast Cancer Now
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists (RCR)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary (BNF)
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 October 2025 | Committee meeting |
| 07 October 2025 | Declaration of interests |
| 03 March 2025 | Invitation to participate |
| 03 March 2025 | Please note this evaluation has been combined with ID6309. The evaluation will continue under ID5121. |
| 03 March 2025 | In progress. MAA review of TA704 and TA862 |
| 07 January 2025 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual